Impax Laboratories, Inc, a specialty pharmaceutical company, has received US Food and Drug Administration (FDA) approval for generic Mestinon Timespan tablets (pyridostigmine bromide extended release), 180 mg. The company is going for commercialisation of this product.
Pfizer’s injectable contraceptive, Sayana®Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. This follows the recent approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of an update to the Sayana® Press label, adding the option for self-injection by women when considered appropriate by a healthcare professional (HCP).
ERYTECH Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, received a new patent in the United States.
Pfizer, a Rs. 1,800 crore plus Indian subsidiary of Pfizer Inc. USA, has entered into a business transfer agreement for the transfer of the company’s business at the Thane plant to Vidhi Research and Development LLP for Rs. 178 crore. Upon the conclusion of the BTA, all current workmen at the plant shall be transferred to the buyer so as to facilitate manufacturing operations.
GE Healthcare, the $18 billion healthcare technology division of GE, created a new business unit, Sustainable Healthcare Solutions (SHS), that will develop high-value, low-cost technologies and healthcare delivery solutions across multiple care settings.
Akorn, Inc., a leading specialty pharmaceutical company, has launched doxercalciferol injection solution, 4 mcg/2 ml in 2ml single-use vials. Akorn's product is therapeutically equivalent to Hectorol injection, marketed by Genzyme Corporation.
8K Miles Software Services Ltd, a leading provider of secure cloud solutions, acuire US-based NexAge Technologies, a leading regulatory compliance and technology solutions company in the life sciences sector. The agreement includes acquisition of intellectual property (IP), technical solutions, client contracts, and employees.
Jubilant Life Sciences Ltd, an integrated global pharmaceuticals company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (FDA) for zolmitriptan orally disintegrating tablets, 2.5 mg and 5 mg the generic version of Zomig-ZMT (AstraZeneca), which is used for acute treatment of migraine headaches in adults.
Sun Pharmaceutical Industries Ltd. and Strides Arcolab Ltd. have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the central nervous system (CNS) segment in India.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company's (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
